Estrogen receptor (ER) positive breast cancers account for the majority (70%‐80%) of breast cancers.1, 2 Tamoxifen (TAM), an ER antagonist, is a first line of therapeutic drug for pre‐menopausal patients with ER+ breast cancer. This evidence concerns the gene ESR1 and breast cancer.